Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 7,863 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,863 shares of the company’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $562,283.13. Following the sale, the insider owned 217,126 shares of the company’s stock, valued at $15,526,680.26. This trade represents a 3.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, April 27th, Jason Adair sold 688 shares of Liquidia stock. The stock was sold at an average price of $41.65, for a total value of $28,655.20.

Liquidia Trading Up 7.4%

Liquidia stock opened at $76.49 on Wednesday. Liquidia Corporation has a 52 week low of $14.04 and a 52 week high of $82.96. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The firm has a market capitalization of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55. The business’s 50-day simple moving average is $66.37 and its 200-day simple moving average is $47.52.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s revenue was up 4187.1% on a year-over-year basis. Equities research analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of Liquidia in a report on Monday, May 11th. Wells Fargo & Company raised their price target on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Raymond James Financial restated a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a report on Thursday, June 4th. Finally, Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $68.88.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. Handelsbanken Fonder AB bought a new position in shares of Liquidia during the 2nd quarter worth about $1,993,000. Fulcrum Equity Management bought a new stake in Liquidia in the second quarter valued at about $399,000. Fluent Financial LLC acquired a new position in Liquidia in the second quarter worth about $287,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the second quarter worth about $1,395,000. Finally, Seven Fleet Capital Management LP lifted its stake in Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares during the period. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).